The latest release of Sophia AI merges imaging analysis with genomic medicine in pursuit of better diagnosis and treatment.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Sophia Genetics has received a CE-IVD mark for a sequencing-based test that, combined with data analytics, is meant to improve detection of leukemia.
The financing will be used to advance the firm's drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
Rhythm is using WuXi's artificial intelligence capabilities to support drug development targeting pathways associated with genetic obesity syndromes.
Three-month-old health data integrator Datavant hopes its analytics technology can improve the speed and success of clinical trials.
The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
The companies plan to combine their expertise in artificial intelligence and genomic data analyses to develop new precision medicine tools.
The Boston-based hospitals will provide Berg access to clinically annotated patient-derived specimens to track neurological disease pathology and develop diagnostic tools.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.